Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

EUROTARGET

Financiado

Cerrado

European collaborative project on Targeted therapy in renal cell cancer genetic...

European collaborative project on Targeted therapy in renal cell cancer genetic and tumor related biomarkers for response and toxicity Each year more than 63,000 new cases of kidney cancer are diagnosed in the European Union. Approx. 50% of all patients have metastasized renal cell cancer (mRCC) at presentation or develop metastases during follow-up. 5-year relat... ver más

31/08/2016

STICHTING RADBOUD...

8M€

Presupuesto del proyecto: 8M€

Líder del proyecto

STICHTING RADBOUD UNIVERSITEIT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 15 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2016-08-31 No tenemos la información de la convocatoria

0% 77% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

15 Participantes

STICHTING RADBOUD UNIVERSITE...

0.00€ | Lider

FUNDACIO INSTITUT D?INVESTIG...

N.D. | Participante

TAT

N.D. | Participante

UNIVERSITATSKLINIKUM JENA

N.D. | Participante

Proyectos interesantes

EPIPHARM

Medical Technol...

Data Science

149K€ Cerrado

FUNCTIONAL GENOMICS

Medical Technol...

Data Science

2M€ Cerrado

RTI2018-095039-B-I00

Medical Technol...

Data Science

109K€ Cerrado

PID2021-128312OB-I00

Medical Technol...

Data Science

196K€ Cerrado

INITIATOR

Medical Technol...

Data Science

150K€ Cerrado

PERSMEDOMICS

Medical Technol...

Data Science

100K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

STICHTING RADBOUD UNIVERSITEIT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 8M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Each year more than 63,000 new cases of kidney cancer are diagnosed in the European Union. Approx. 50% of all patients have metastasized renal cell cancer (mRCC) at presentation or develop metastases during follow-up. 5-year relative survival of mRCC has been extremely poor: between 5 and 10%. In the past few years, so-called targeted therapies that suppress angiogenesis have changed the clinical practice for patients with mRCC dramatically. Both response and toxicity to these expensive drugs is, however, extremely variable. With an increasing number of compounds becoming available, choice of compounds and sequence is becoming extraordinary challenging. Classical patient and tumor characteristics appear to have poor predictive ability. The aim of this project is to identify germline genetic markers that predict response and toxicity (by the use of high-resolution whole genome SNP arrays in groups of hundreds of patients treated with different agents), identify expression and epigenetic markers in tumors that predict response (by comparing expression and methylome arrays and kinase profiles in frozen tumor tissue from groups of patients who do (N=30) and do not (N=30) respond to different agents), to integrate these data from different platforms by means of bioinformatics and to conduct focused functional studies on the results in order to improve understanding of the critical molecular and resistance pathways involved. A large European consortium that has recruited and will recruit large numbers of patients ensures that the new markers identified in a first discovery phase can be tested in a subsequent replication phase. We have the ambition to define new validated risk stratification criteria to be used in personalized patient management. These criteria allow prediction of individual therapy response and resistance and will enable the monitoring of successful treatment outcome while reducing unnecessary drug use and expense.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores